Atara Biotherapeutics, Inc. (ATRA)


+0.06 (+1.78%)
Symbol ATRA
Price $3.44
Beta 1.493
Volume Avg. 2.02M
Market Cap 321.316M
Shares () -
52 Week Range 2.83-20.04
1y Target Est -
DCF Unlevered ATRA DCF ->
DCF Levered ATRA LDCF ->
ROE -122.17% Strong Sell
ROA -88.08% Strong Sell
Operating Margin -
Debt / Equity 77.11% Buy
P/E -
P/B 1.54 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest ATRA news

Dr. Pascal Touchon
NASDAQ Global Select

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.